Evidence map›Paper›PMID 38012013›Full record

ReviewCold Spring Harbor perspectives in biology2024

Building Representation Learning Models for Antibody Comprehension.

Justin Barton, Aretas Gaspariunas, Jacob D Galson, Jinwoo Leem

Abstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Data-optimal scaling of paired antibody language models.bioRxiv : the preprint server for biology · 2025
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Justin BartonAlchemab Therapeutics Ltd, London N1C 4AX, United Kingdom.
Aretas GaspariunasAlchemab Therapeutics Ltd, London N1C 4AX, United Kingdom.
Jacob D GalsonAlchemab Therapeutics Ltd, London N1C 4AX, United Kingdom.
Jinwoo LeemAlchemab Therapeutics Ltd, London N1C 4AX, United Kingdom jin@alchemab.com jake@alchemab.com.ORCID 0000-0002-7817-3644

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies are versatile proteins with both the capacity to bind a broad range of targets and a proven track record as some of the most successful therapeutics. However, the development of novel antibody therapeutics is a lengthy and costly process. It is challenging to predict the functional and biophysical properties of antibodies from their amino acid sequence alone, requiring numerous experiments for full characterization. Machine learning, specifically deep representation learning, has emerged as a family of methods that can complement wet lab approaches and accelerate the overall discovery and engineering process. Here, we review advances in antibody sequence representation learning, and how this has improved antibody structure prediction and facilitated antibody optimization. We discuss challenges in the development and implementation of such models, such as the lack of publicly available, well-curated antibody function data and highlight opportunities for improvement. These and future advances in machine learning for antibody sequences have the potential to increase the success rate in developing new therapeutics, resulting in broader access to transformative medicines and improved patient outcomes.

Indexed as

ComprehensionMachine LearningHumansProteinsProteins

Identifiers

PMID38012013
PMCPMC10910360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.